Welcome to our dedicated page for Chimerix news (Ticker: CMRX), a resource for investors and traders seeking the latest updates and insights on Chimerix stock.
Chimerix, Inc. (NASDAQ: CMRX) is a clinical-stage biopharmaceutical company pioneering therapies for rare cancers and viral infections. This dedicated news hub provides investors and medical professionals with essential updates on clinical developments, regulatory milestones, and corporate announcements.
Access real-time information about Chimerix's innovative pipeline, including its lead candidate dordaviprone for H3 K27M-mutant glioma and ongoing research in antiviral treatments. The curated collection features press releases, financial reports, and scientific presentations – all vital for understanding the company's progress in addressing unmet medical needs.
Key content categories include clinical trial results, FDA communications, partnership announcements, and financial performance updates. Each update is carefully verified to ensure accuracy and relevance for stakeholders monitoring therapeutic advancements in oncology and infectious diseases.
Bookmark this page for streamlined access to Chimerix's latest developments. Check regularly for critical updates on drug approvals, research breakthroughs, and strategic initiatives that shape the company's trajectory in biopharmaceutical innovation.
Chimerix (NASDAQ:CMRX) announced a contract worth up to $25.3 million from the Public Health Agency of Canada for the procurement of TEMBEXA (brincidofovir). This agreement underscores the significance of TEMBEXA as a medical countermeasure. The delivery is expected to take place before Chimerix's pending transaction with Emergent BioSolutions. TEMBEXA is approved for smallpox and Chimerix will earn revenues before closing the Emergent deal and a 15%-20% royalty on future sales. The transaction's completion requires several conditions, including regulatory approvals.
Chimerix (NASDAQ:CMRX) announced a $9.3 million agreement to procure TEMBEXA® (brincidofovir) internationally, bolstering its role as a medical countermeasure. This contract aims to meet strategic stockpile needs and fulfill obligations linked to a potential BARDA contract. Chimerix's revenue from TEMBEXA before the pending transaction with Emergent BioSolutions will remain with the company, while post-transaction, it will earn royalties of 15% on international and 20% on U.S. sales exceeding 1.7 million treatment courses. Closing of the deal is contingent upon several conditions.
Chimerix (NASDAQ:CMRX) announced that CEO Mike Sherman will present a corporate overview at the Jefferies Healthcare Conference on June 8, 2022, at 3:30 p.m. in New York City. The presentation will highlight Chimerix's mission to develop medicines to improve and extend the lives of patients with serious diseases. A live audio webcast of the presentation will be accessible on the Investor Relations section of Chimerix’s website and archived for 90 days.
Chimerix's leading clinical program, ONC201, targets H3 K27M-mutant glioma.
DURHAM, N.C., May 17, 2022 (GLOBE NEWSWIRE) -- Chimerix (NASDAQ:CMRX) announced that CEO Mike Sherman will present a pre-recorded corporate update at the H.C. Wainwright Global Investment Conference on May 24, 2022, at 7:00 a.m. ET. An audio webcast of the presentation will be accessible on Chimerix's Investor Relations webpage and archived for approximately 90 days. Chimerix focuses on developing medicines to improve the lives of patients with serious diseases, with its leading program being ONC201 for H3 K27M-mutant glioma.
Chimerix (CMRX) has secured up to $337.5 million from Emergent BioSolutions through the sale of worldwide rights to TEMBEXA, with an upfront payment of $225 million. The company is shifting focus to the development of ONC201 for H3 K27M-mutant glioma, planning a Phase 3 study by year-end 2022. The DSTAT program has been terminated to streamline efforts. Financially, Chimerix reported a net loss of $24.8 million for Q1 2022, a decrease from a $97.4 million loss in Q1 2021, while revenues dropped to $15,000 from $1.4 million a year earlier.
Chimerix (NASDAQ:CMRX) announced a definitive agreement with Emergent BioSolutions to acquire exclusive rights to brincidofovir, including TEMBEXA, for $225 million plus potential milestone payments of up to $100 million. The deal enhances Chimerix's balance sheet, allowing focus on its development pipeline while maintaining participation in TEMBEXA's economics through royalties and milestone payments. Closing conditions include a procurement contract with BARDA. TEMBEXA, approved by the FDA for smallpox, represents a strategic asset in biodefense.
Chimerix (NASDAQ:CMRX) announced that Josh Allen, Ph.D., its Chief Technology Officer of Imipridones, will participate in a panel discussion titled “Exploring New Targets for Pediatric Brain Cancer.” This event is hosted by Maxim Group and is scheduled for May 19, 2022, at 9:00 a.m. ET. An audio webcast of the event will be accessible on Chimerix's Investor Relations website for approximately 90 days. Chimerix is dedicated to developing medicines that enhance and prolong patients' lives. Notably, the FDA approved its drug TEMBEXA for smallpox treatment in June 2021.
Chimerix (NASDAQ:CMRX) will host a live conference call on May 16, 2022, at 8:30 a.m. ET to discuss its Q1 2022 financial results and provide a business overview. The call can be accessed via phone or through a webcast on the company's website. Chimerix focuses on developing medicines for serious diseases and has received FDA approval for TEMBEXA for smallpox. Additionally, the company is advancing its clinical programs for ONC201 and dociparstat sodium (DSTAT) in oncology.
Chimerix (NASDAQ:CMRX) announced that CEO Mike Sherman will present a pre-recorded talk at the Maxim Group 2022 Virtual Growth Conference from March 28-30, 2022. An audio webcast of the presentation will be accessible on Chimerix's Investor Relations website and archived for 90 days. Chimerix focuses on developing medicines for severe diseases, having received FDA approval for TEMBEXA to treat smallpox. The company's advanced clinical programs include ONC201 for glioma and dociparstat sodium (DSTAT) for acute myeloid leukemia.
Chimerix (NASDAQ:CMRX) announced its Q4 and full-year 2021 financial results, reporting a net loss of $39.5 million for Q4 and $173.2 million for the year. Revenue dropped to $46,000 in Q4 compared to $1.1 million in 2020, driven by the end of a BARDA contract. Notably, Chimerix achieved FDA approval for TEMBEXA as a smallpox treatment and reported promising data for ONC201 in glioma therapy. The company has submitted a BARDA RFP response regarding TEMBEXA and accepted preclinical data of CMX521 for a presentation at an antiviral conference.
FAQ
What is the current stock price of Chimerix (CMRX)?
What is the market cap of Chimerix (CMRX)?
